These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32882179)

  • 61. Aptamer inhibitor selection of SpyCas9 through CE-SELEX.
    Yang G; Wang H; Jiang G; Zhao L; Qu F
    Talanta; 2024 Jun; 273():125837. PubMed ID: 38479030
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Search and Localization Dynamics of the CRISPR-Cas9 System.
    Lu Q; Bhat D; Stepanenko D; Pigolotti S
    Phys Rev Lett; 2021 Nov; 127(20):208102. PubMed ID: 34860046
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cas9 activates the p53 pathway and selects for p53-inactivating mutations.
    Enache OM; Rendo V; Abdusamad M; Lam D; Davison D; Pal S; Currimjee N; Hess J; Pantel S; Nag A; Thorner AR; Doench JG; Vazquez F; Beroukhim R; Golub TR; Ben-David U
    Nat Genet; 2020 Jul; 52(7):662-668. PubMed ID: 32424350
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sumoylation of Cas9 at lysine 848 regulates protein stability and DNA binding.
    Ergünay T; Ayhan Ö; Celen AB; Georgiadou P; Pekbilir E; Abaci YT; Yesildag D; Rettel M; Sobhiafshar U; Ogmen A; Emre NT; Sahin U
    Life Sci Alliance; 2022 Apr; 5(4):. PubMed ID: 35022246
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Increasing the Activity of the High-Fidelity SpyCas9 Form in Yeast by Directed Mutagenesis of the PAM-Interacting Domain.
    Davletshin AI; Matveeva AA; Bachurin SS; Karpov DS; Garbuz DG
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203615
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Nucleolus localization of SpyCas9 affects its stability and interferes with host protein translation in mammalian cells.
    Tan R; Du W; Liu Y; Cong X; Bai M; Jiang C; Li Z; Tan M; Ma DK; Huang Q; Jiang W; Dang Y
    Genes Dis; 2022 May; 9(3):731-740. PubMed ID: 35782966
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The effect of histone deacetylase inhibitors on the efficiency of the CRISPR/Cas9 system.
    Björnson Y; Huang CY; Rollins JL; Castañeda G; Kaur N; Yamamoto E; Johnston JM
    Biochem Biophys Rep; 2023 Sep; 35():101513. PubMed ID: 37521376
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Investigation of Cas9 antibodies in the human eye.
    Toral MA; Charlesworth CT; Ng B; Chemudupati T; Homma S; Nakauchi H; Bassuk AG; Porteus MH; Mahajan VB
    Nat Commun; 2022 Feb; 13(1):1053. PubMed ID: 35217666
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The novel anti-CRISPR AcrIIA22 relieves DNA torsion in target plasmids and impairs SpyCas9 activity.
    Forsberg KJ; Schmidtke DT; Werther R; Uribe RV; Hausman D; Sommer MOA; Stoddard BL; Kaiser BK; Malik HS
    PLoS Biol; 2021 Oct; 19(10):e3001428. PubMed ID: 34644300
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Identification of preexisting adaptive immunity to Cas9 proteins in humans.
    Charlesworth CT; Deshpande PS; Dever DP; Camarena J; Lemgart VT; Cromer MK; Vakulskas CA; Collingwood MA; Zhang L; Bode NM; Behlke MA; Dejene B; Cieniewicz B; Romano R; Lesch BJ; Gomez-Ospina N; Mantri S; Pavel-Dinu M; Weinberg KI; Porteus MH
    Nat Med; 2019 Feb; 25(2):249-254. PubMed ID: 30692695
    [TBL] [Abstract][Full Text] [Related]  

  • 71.
    Skeens E; East KW; Lisi GP
    Biomol NMR Assign; 2021 Apr; 15(1):25-28. PubMed ID: 32935194
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association of Therapeutic Dose of Valproic Acid and Plasma Glycine Levels in Epileptic Patients.
    Ahmad S; Aamir M; Kirmani SI; Haroon ZH; Munir MU; Khalid UB
    J Coll Physicians Surg Pak; 2021 Sep; 31(9):1020-1023. PubMed ID: 34500514
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of l-carnitine supplementation in patients with childhood-onset epilepsy prescribed valproate.
    Okumura A; Takagi M; Numoto S; Iwayama H; Azuma Y; Kurahashi H
    Epilepsy Behav; 2021 Sep; 122():108220. PubMed ID: 34371461
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Initial levetiracetam versus valproate monotherapy in antiseizure medicine (ASM)-naïve pediatric patients with idiopathic generalized epilepsy with tonic-clonic seizures.
    Abdelmesih SK; Elkhateeb N; Zakaria M; Girgis MY
    Seizure; 2021 Oct; 91():263-270. PubMed ID: 34246881
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cosmetic adverse effects of antiseizure medications; A systematic review.
    Asadi-Pooya AA; Rostaminejad M; Zeraatpisheh Z; Mirzaei Damabi N
    Seizure; 2021 Oct; 91():9-21. PubMed ID: 34052629
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A PROTAC targets splicing factor 3B1.
    Gama-Brambila RA; Chen J; Zhou J; Tascher G; Münch C; Cheng X
    Cell Chem Biol; 2021 Nov; 28(11):1616-1627.e8. PubMed ID: 34048672
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Skeletal muscle regeneration via the chemical induction and expansion of myogenic stem cells in situ or in vitro.
    Fang J; Sia J; Soto J; Wang P; Li LK; Hsueh YY; Sun R; Faull KF; Tidball JG; Li S
    Nat Biomed Eng; 2021 Aug; 5(8):864-879. PubMed ID: 33737730
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Chem-CRISPR/dCas9FCPF: a platform for chemically induced epigenome editing.
    Altinbay M; Wang J; Chen J; Schäfer D; Sprang M; Blagojevic B; Wölfl S; Andrade-Navarro MA; Dikic I; Knapp S; Cheng X
    Nucleic Acids Res; 2024 Oct; 52(19):11587-11601. PubMed ID: 39315698
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Molecular Marvels: Small Molecules Paving the Way for Enhanced Gene Therapy.
    Hasselbeck S; Cheng X
    Pharmaceuticals (Basel); 2023 Dec; 17(1):. PubMed ID: 38256875
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Small Molecules for Enhancing the Precision and Safety of Genome Editing.
    Shin S; Jang S; Lim D
    Molecules; 2022 Sep; 27(19):. PubMed ID: 36234804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.